Medifast
MED
202 hedge funds and large institutions have $781M invested in Medifast in 2020 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 57 increasing their positions, 77 reducing their positions, and 48 closing their positions.
8% less funds holding
Funds holding: 219 → 202 (-17)
8.53% less ownership
Funds ownership: 114.82% → 106.29% (-8.5%)
26% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 77
27% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 48
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
47% less capital invested
Capital invested by funds: $1.46B → $781M (-$681M)
73% less call options, than puts
Call options by funds: $6.13M | Put options by funds: $22.8M
Top Buyers
Top Sellers
MED Hedge Fund Activity: Q1 2020 in Review
202 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Medifast (MED) for Q1 2020, worth a combined $781M — down 47% from $1.46B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of MED and 35 opened new positions — a net loss of 13 holders — while 77 trimmed existing stakes and 57 added.
The largest buyer was Nantahala Capital Management, adding an estimated $13M. The largest seller was Miller Value Partners, cutting an estimated $19.4M.
- 202 institutional investors held Medifast (MED) as of Q1 2020, down from 219 in Q4 2019.
- Funds reported $781M of Medifast stock for Q1 2020, down 47% quarter-over-quarter.
- 35 funds opened new Medifast positions in Q1 2020 and 48 closed out, a net change of -13 holders.
- The largest Medifast buyer in Q1 2020 was Nantahala Capital Management, an estimated $13M added.
- The largest Medifast seller in Q1 2020 was Miller Value Partners, an estimated $19.4M sold.
Based on aggregated 13F filings for Q1 2020.